"UI Health Cancer Center, a 21st century model of community-based health care, is dedicated to eradicating cancer through an integrated program of excellence in clinical care, research and education for everyone in Illinois, regardless of race, ethnicity and socioeconomic status. We tackle cancer on all fronts working collaboratively with approximately 100 Cancer Center members from eleven colleges across all three campuses of the University of Illinois. In this age of precision medicine, UI Health Cancer Center is dedicated to ensuring that medicine includes all individuals equally. Our research spans cancer biology, genetics, therapeutics, diagnostics and imaging, cancer prevention, control and early detection, and more."

During the past decade, University of Illinois Cancer Center conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 46 clinical trials were completed, i.e. on average, 109.5% percent of trials that started reached the finish line to date. In the past 5 years, 18 clinical trials started and 16 clinical trials were completed. i.e. 88.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of Illinois Cancer Center" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 20 trials, followed by "Children's Oncology Group" with 17 trials sponsored, "University of Illinois at Chicago" with 14 trials sponsored, "SWOG Cancer Research Network" with 8 trials sponsored and "Eastern Cooperative Oncology Group" with 8 trials sponsored. Other sponsors include 45 different institutions and companies that sponsored additional 45 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of Illinois Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 65 trials as a collaborator, "Big Ten Cancer Research Consortium" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 5 trials as a collaborator, "Cancer and Leukemia Group B" with 4 trials as a collaborator and "Merck Sharp & Dohme LLC" with 4 trials as a collaborator. Other collaborators include 38 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "University of Illinois Cancer Center" are "Leukemia" (10 trials), "Lung Cancer" (7 trials), "Lymphoma" (7 trials), "Prostate Cancer" (6 trials) and "Breast Cancer" (5 trials). Many other conditions were trialed in "University of Illinois Cancer Center" in a lesser frequency.

Most popular intervention types in "University of Illinois Cancer Center" are "Drug" (90 trials), "Other" (22 trials), "Biological" (17 trials), "Radiation" (17 trials) and "Procedure" (15 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (11 trials), "filgrastim" (9 trials), "placebo" (9 trials), "radiation therapy" (9 trials) and "doxorubicin hydrochloride" (8 trials). Other intervention names were less common.

The vast majority of trials in "University of Illinois Cancer Center" are 95 trials for "All" genders, 13 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "University of Illinois Cancer Center". 1 are not yet recruiting, 17 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 63 completed trials in University of Illinois Cancer Center, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in University of Illinois Cancer Center, 19 "Phase 1" clinical trials were conducted, 49 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 6 trials that are defined as “Not Applicable".